Meeting Urgent Needs in Surveillance and Diagnostics. Zika

迫切需要监测和诊断。寨卡 Firebird Biomolecular Sciences LLC 佛罗里达医学昆虫学实验室，佛罗里达大学 Steven A. Benner 巴里W. Alto 摘要 寨卡病毒对美国公民和世界公民的潜在危害不需要 讨论我们仍在了解该病毒的分布和对人类发展的影响， 子宫，以及其在患者唾液、性流体和尿液中的分布。有几十个案子 在撰写本文时，美国大部分是在海外获得的，公共部门的校外研究项目。 卫生机构被要求寻求更好的公共卫生监测技术， 寨卡病毒的人类诊断工具。例如，在巴西，迫切需要的是一种测试， 在公共诊所区分登革热、基孔肯雅病和寨卡病毒;在这个时候，这种区分是 根据对病人的询问，就各种症状出现的时间进行了调查。 症状这里提出的工作将为寨卡病毒提供这些技术和工具。 但是，这项工作将提供更多。今天，NIAID，CDC和其他公共卫生单位 负责管理传染病疫情从一种疾病转移到另一种疾病， 疫情和新闻周期。这是低效的，在最好的。在新兴时代提供有效的公共卫生服务- 研究疾病需要一个强大且可复制的技术平台，该平台足够灵活， 检查任何新出现的传染病，而不出现危机。这里提出的工作提供了这样一个平台 作为其调查寨卡病毒并将其与其他虫媒病毒区分开来的能力的一部分， 来自“合成生物学”领域的创新，包括人工扩增的遗传信息， 信息系统（AEGIS），自回避分子识别系统（SAMRS），双链核苷酸， 音译和基于进化的虫媒病毒序列分析，在弗洛尔- 伊达医学昆虫学实验室（FMEL），该实验室有感染寨卡病毒、登革热和 基孔肯雅热，以及合成生物学和诊断技术的一系列创新者火鸟。 这个R21项目将首先将寨卡病毒添加到已经建立的检测其他22种虫媒病毒的试剂盒中， 13我们将对扩展套件进行基准测试，将其交付给FMEL的beta测试人员， 使用Luminex仪器进行读数。这种独立的测试保证了科学的严谨性， 在12个月内完成。在第二年，我们将寻求一个更简单的系统，集中在特定地理位置的多功能 目标集，增加双向管理RNA病毒的序列进化，在10倍目标中取代Luminex 通过基于4x 4微阵列的读出进行测定，并尽可能地朝向10 x多重系统 可以在野外检测10只蚊子。为此，我们将实现以下具体目标： 该项目的成果将包括新的寨卡科学，以及将允许公共卫生服务的工具包。 享受这些试剂创新在管理寨卡疫情方面的优势，就像这些优势一样， 现在在许多产品中，包括FDA批准的产品，用于人类诊断。

Urgent Needs in Surveillance and Diagnostics. Zika Firebird Biomolecular Sciences LLC Florida Medical Entomology Laboratory, the University of Florida Steven A. Benner Barry W. Alto ABSTRACT The potential hazards of the Zika virus to both American citizenry and citizens of the world need no discussion. We are still learning the distribution and impact of the virus on human development in utero, as well as its distribution in patient saliva, sexual fluids, and urine. With several dozen cases in the US at the time of this writing, most obtained overseas, the extramural research programs of public health agencies are being asked to seek better public health surveillance technologies and immediate human diagnostics tools for Zika. For example, in Brazil, the immediate need is a test that to distinguish between dengue, chikungunya, and Zika in public clinics; at this time, this distinction is made based on interrogation of patients with respect to the timing of the appearance of various symptoms. The work proposed here will deliver those technologies and tools for Zika. However, this work will provide more. Today, the NIAID, CDC, and other public health units responsible for managing infectious disease outbreaks move from disease to disease, with each new outbreak and news cycle. This is inefficient, at best. Efficient public health services in an age of emerg- ing diseases need a robust and reproducible technology platform that is sufficiently flexible to sur- vey for any emerging infectious diseases without crisis. The work proposed here offers such a platform as part of its ability to survey for Zika, and distinguish it from other arboviruses, based on reagent innovations drawn from the field of “synthetic biology”, including artificially expanded genetic infor- mation systems (AEGIS), self-avoiding molecular recognition systems (SAMRS), biversal nucleotides, transliteration, and evolution-based arbovirus sequence analysis, in a collaboration between the Flor- ida Medical Entomology Laboratory (FMEL), which has live lab-infected mosquitoes with Zika, dengue, and chikungunya, and Firebird, a serial innovator in synthetic biology and diagnostics technology. This R21 project will first add Zika to an already established kit that detects 22 other arboviruses, common and exotic.13 We will benchmark that expanded kit, delivering it to beta testers in FMEL, where multiplexed readout is done using a Luminex instrument. This independent testing guarantees scientific rigor, and will be done by Month 12. In Year 2, we will seek a simpler system, focusing the multiplex on geography-specific target sets, adding biversals to manage sequence evolution of the RNA viruses, replacing Luminex in 10x target assays by a readout based on a 4x4 micro array, and going as far as possible towards a 10x multiplex system that can assay ~ 10 mosquitoes in the field. Towards these ends, we will meet the following specific aims: The outcome of this project will include new Zika science, as well as kits that will allow public health services to enjoy the advantages of these reagent innovations in managing the Zika outbreak, just as those advantages are now enjoyed in many products, including FDA-approved products, for human diagnostics.